Answers are grounded in this paper and cite their sources.
Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease in which interactions among the intestinal microbiome, bile acid metabolism, and immune regulation may influence disease pathogenesis, progression, and therapeutic response. This narrative review synthesizes clinical and experimental evidence concerning the microbiome-bile acid-immune axis and its relevance to emerging therapeutic strategies. Studies involving patients with PBC have identified alterations in intestinal microbial composition and diversity, disturbances in bile acid profiles, and microbial signatures associated with biochemical response to ursodeoxycholic acid. Microbiome-derived metabolites, including short-chain fatty acids, secondary bile acids, and tryptophan derivatives, may influence intestinal barrier integrity, bile acid receptor signaling, and innate and adaptive immune responses. However, much of the mechanistic evidence originates from experimental models or other liver and immune-mediated diseases, and causal relationships in human PBC remain incompletely established. Emerging peroxisome proliferator-activated receptor agonists, particularly elafibranor and seladelpar, have demonstrated biochemical efficacy, while the potential contribution of microbiome-mediated mechanisms to their therapeutic effects remains uncertain. Microbiome-directed interventions, including probiotics and fecal microbiota transplantation, remain investigational in PBC. Longitudinal multi-omics investigations, functional studies, and prospective biomarker validation are essential to establish clinically relevant mechanisms and evaluate opportunities for more personalized therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Kotsiri et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: